丹参干预肿瘤和缺血性疾病血管生成研究进展

血管异常增生的疾病如肿瘤治疗要抗血管生成,而缺血性疾病的治疗要促血管生成。肿瘤与缺血后新生血管主要区别在于血管的成熟度和稳定性不同,而血管生成是个复杂的过程。活血化瘀代表中药丹参普遍应用于肿瘤和缺血性疾病。综述近年来对丹参及其水溶性和脂溶性成分影响血管生成的研究进展,丹参各种成分表现出抗血管生成和促血管生成双重调控作用。丹参对血管生成表现出的调控效应可能与实验条件的不同,丹参成分的多样性,血管生成的复杂性,以及不同病理状态下体内分布的差异有关系。

Research progress on intervention by Salviae Miltiorrhizae Radix et Rhizoma on angiogenesis of tumor and ischemic disease

Diseases with excessive angiogenesis such as tumors need to be treated with anti-angiogenesis agents, while ischemic diseases need to be treated with pro-angiogenesis agents. Salviae Miltiorrhizae Radix et Rhizoma, the representative drug which promotes circulation and resolves clots, was widely used in treating tumors and ischemic diseases. This review focused on the current research on the angiogenic effect of Salviae Miltiorrhizae Radix et Rhizoma and its water-soluble or fat-soluble components. It was found that there are some controversy reports. Both pro-angiogenic and anti-angiogenic effects of Salviae Miltiorrhizae Radix et Rhizoma and its components have been reported. The major difference between tumor and ischemia is the maturity and stability of vessels. Angiogenesis is a complex process involving many signaling molecules. Therefore, the components of Salviae Miltiorrhizae Radix et Rhizoma will regulate the levels and functions of angiogenesis, and then vessels produce different maturity and stability. Overall, such controversy may be caused by differences in experimental conditions, the diversity of Salviae Miltiorrhizae Radix et Rhizoma components, the complexity of the angiogenic process, and the differences of drug distribution under different pathological states in vivo.